TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00394771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1031
Description: Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1031
Description: Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1031
Description: Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seasonale®
Description: 84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Portia®
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Portia®
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Portia®
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Portia®
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
Study: NCT04236167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment -
Description: UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
Study: NCT01116713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexamethasone
Description: One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homologated placebo.
Description: Patients of the control group received homologated placebo 60 minutes before skin incision
Study: NCT01315041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsicum frutescens fruits, homeopathic medicine
Description: 5 drops, PO, 3 times a day, during 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert alcoholic solution
Description: 5 drops, PO, 3 times a day, during 16 weeks
Study: NCT01592292

Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab as per physician's discretion.

Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab as per physician's discretion.

Intervention type: DRUG
Intervention: Etanercept
Description: Etanercept as per physician's discretion.

Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab as per physician's discretion.
Study: NCT03564080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined - PAD and CAD
Description: 12-week supervised exercise programme in a hospital setting
Study: NCT01783821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
Study: NCT04028622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCAD (telemedicine anesthesia consultation)
Description: Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
Study: NCT02332239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDOVE Intervention (ED+text)
Description: 1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored text-message program

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (EUC)
Description: 1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program
Study: NCT03433313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG12014
Description: EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
Study: NCT04477694

Intervention type: PROCEDURE
Intervention: colonoscopy under sedoanalgesia
Description: Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.

Intervention type: PROCEDURE
Intervention: colonoscopy under sedoanalgesia
Description: Colonoscopy is a widely used method for diagnosing and treating colonic diseasea with a thin, flexible camera.
Study: NCT02764567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oil
Description: Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
Study: NCT03059199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Arm Feasibility Study
Description: Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
Study: NCT01576003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-alanine
Description: 0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
Study: NCT02870205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301 NS
Description: 2 spray in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GOM-NS
Description: 2 spray in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GMM-2 NS
Description: 2 spray in each nostril twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 placebo NS
Description: 2 spray in each nostril twice daily for 14 days
Study: NCT04520581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group O
Description: Endotracheal tube was made O shape by assistants.
Study: NCT03248414

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus sakei
Description: 1 pack contained 5 x 109 cfu
Study: NCT00887380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-radiotherapy commencement of anastrozole
Description: Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
Study: NCT03248414

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus sakei
Description: 1 pack contained 5 x 109 cfu
Study: NCT03449394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training
Description: 4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training
Description: 4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
Study: NCT01561599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BB3
Description: Daily intravenous administration of 2mg/kg for 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Study: NCT02939482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide and normal saline solution
Description: 80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide and normal saline solution
Description: 80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
Study: NCT04636294

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 PCR
Description: SARS-CoV-2 PCR of nasopharyngeal lysate.
Study: NCT03674697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green LED light therapy
Description: You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: White LED light therapy
Description: You will be asked to locate a dark room in your house 8 weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery (8 weeks). You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with your chosen time. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smartphones, tablets, etc.).
Study: NCT04492917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV4
Description: The osteopath was sitting at the head of the examination table, with the subject lying supine. The osteopath approximated with the hands the lateral angles of the occipital squama, taking the cranium into sustained extension. The technique ended when the osteopath perceived the still point, a condition in which the balanced membranous or ligamentous tension is achieved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ST
Description: The subject was lying in the supine position, while the osteopath positioned the index and middle fingers of the caudal hand on either side of the subject's sacrum. Then establishes a point of balance between the coccyx and the vertex facilitating the sacral extension until the achievement of the still point

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham CV4
Description: the sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham ST
Description: The sham intervention was performed by placing the hands in the same position as the corresponding active technique, applying a light touch
Study: NCT01831323

Intervention type: DIETARY_SUPPLEMENT
Intervention: VSL#3
Description: VSL#3

Intervention type: DRUG
Intervention: Rifaximin
Description: Rifaximin

Intervention type: DRUG
Intervention: Mesalazine
Description: Mesalazine

Intervention type: DIETARY_SUPPLEMENT
Intervention: Psyllium
Description: psyllium
Study: NCT05123976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)
Description: After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
Description: After an overnight fast of at least 10 hours, a 1 film-coated tablet was administered orally with 240 mL of water .
Study: NCT03410212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
Study: NCT01777295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EngerixTM-B
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT00887380

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post radiotherapy commencement of anastrozole
Description: Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
Study: NCT01989923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarettes
Description: The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
Study: NCT01997749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketocal 4:1 (Nutricia)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control diet: Regular diet offered at the hospitals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic meals
Study: NCT03605368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Intervention
Description: Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Intervention
Description: Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Modeling Intervention
Description: The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Participants will follow all study procedures with the exception of the VR-based intervention including assessments.
Study: NCT03851614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.